The Burzynski Clinic is a controversial clinic offering an unproven cancer treatment. It was founded in and is located in Texas , United States. It is best known for the controversial "antineoplaston therapy" devised by the clinic's founder Stanislaw Burzynski in the s. Antineoplaston is Burzynski's term for a group of urine-derived peptides, peptide derivatives, and mixtures that Burzynski named to use in his "cancer treatment". There is no accepted scientific evidence of benefit from antineoplaston combinations for various diseases.
|Country:||Turks & Caicos Islands|
|Published (Last):||5 June 2016|
|PDF File Size:||13.59 Mb|
|ePub File Size:||1.32 Mb|
|Price:||Free* [*Free Regsitration Required]|
The Burzynski Clinic is a controversial clinic offering an unproven cancer treatment. It was founded in and is located in Texas , United States.
It is best known for the controversial "antineoplaston therapy" devised by the clinic's founder Stanislaw Burzynski in the s.
Antineoplaston is Burzynski's term for a group of urine-derived peptides, peptide derivatives, and mixtures that Burzynski named to use in his "cancer treatment". There is no accepted scientific evidence of benefit from antineoplaston combinations for various diseases.
The clinic has been the focus of criticism primarily due to the way its antineoplaston therapy is promoted, the costs for people with cancer participating in "trials" of antineoplastons, problems with the way these trials are run, and legal cases brought as a result of the sale of the therapy without state board approval.
Burzynski graduated from the Medical Academy in Lublin   earning a Ph. Burzynski moved to the United States in , working at Baylor College until , when he established the Burzynski Research Laboratory where he administered antineoplaston therapy, initially to 21 patients but then more widely as "experimental" treatment. This opened him up to "charges of unethical conduct and to the suspicion he had become a merchant of false hope", which led to several instances of media controversy.
Burzynski founded the Burzynski Research Institute in Antineoplaston is a name coined by Burzynski for a group of peptides , peptide derivatives, and mixtures that he uses as an alternative cancer treatment. Antineoplaston therapy has been offered in the U. The compounds are not licensed as drugs but are instead sold and administered as part of clinical trials at the Burzynski Clinic and the Burzynski Research Institute.
Burzynski stated that he began investigating the use of antineoplastons after detecting what he considered significant differences in the presence of peptides between the blood of cancer patients and a control group. Since similar peptides had been isolated from urine, early batches of Burzynski's treatment were isolated from urine. The first active peptide fraction identified was called antineoplaston A 3-phenylacetylamino-2,6-piperidinedione. From A, antineoplaston AS was derived — a mixture of phenylacetic acid and phenylacetylglutamine.
Since , the clinic has marketed itself as offering "personalized gene-targeted cancer therapy", which has stirred further controversy, as the treatment bears no relationship to gene-targeted therapy and only superficially incorporates elements of personalized medicine. According to the National Cancer Institute , as of April , "no phase III randomized, controlled trials of antineoplastons as a treatment for cancer have been conducted.
Publications have taken the form of case reports, phase I clinical trials, toxicity studies, and phase II clinical trials",  and "for the most part, these publications have been authored by the developer of the therapy, Dr.
Burzynski, in conjunction with his associates at the Burzynski Clinic. Although these studies often report remissions, other investigators have not been successful in duplicating these results. Since the mids, Burzynski registered some sixty clinical trials of antineoplastons and, in December , a Phase III trial which did not open for patient recruitment.
Burzynski has not published full results for any of these. All trials were paused no new patients allowed following a FDA inspections which found for the third consecutive time significant issues with his Institutional Review Board, and, according to papers published in November , substantial issues with the conduct of both the clinic and Burzynski as principal investigator.
Although Burzynski and his associates claim success in the use of antineoplaston combinations for the treatment of various diseases, and some of the clinic's patients say they have been helped,  there is no clinical evidence of the efficacy of these methods. The consensus among the professional community, as represented by the American Cancer Society  and Cancer Research UK  among others, is that antineoplaston therapy is unproven and the overall probability of the treatment turning out to be as claimed is low due to lack of credible mechanisms and the poor state of research after more than 35 years of investigation.
While the antineoplaston therapy is marketed as a non-toxic alternative to chemotherapy, it is a form of chemotherapy with significant known side effects including severe neurotoxicity. Independent scientists have been unable to reproduce the positive results reported in Burzynski's studies: NCI observed that researchers other than Burzynski and his associates have not been successful in duplicating his results,  and Cancer Research UK states that "available scientific evidence does not support claims that antineoplaston therapy is effective in treating or preventing cancer.
There is no convincing evidence from randomized controlled trials in the scientific literature that antineoplastons are useful treatments of cancer, and the U. In , three oncologists were enlisted by the weekly Washington newsletter The Cancer Letter to conduct independent reviews of Burzynski's clinical trial research on antineoplastons.
They concluded that the studies were poorly designed, not interpretable, and "so flawed that it cannot be determined whether it really works". One of them characterized the research as "scientific nonsense". The Memorial Sloan-Kettering Cancer Center has stated: "Bottom Line: There is no clear evidence to support the anticancer effects of antineoplastons in humans.
Available information suggests that health insurance plans often do not reimburse costs linked to this treatment. Recent criticism has focused on the use of crowdfunding to raise the costs of quack treatments, including specifically hundreds of thousands of dollars in the case of the Burzynski Clinic. Burzynski's use and advertising of antineoplastons as an unapproved cancer therapy were deemed to be unlawful by the U. FDA and the Texas Attorney General ,   and limits on the sale and advertising of the treatment were imposed as a result.
In , the FDA issued a warning letter to the Burzynski Research Institute, stating that an investigation had determined the Burzynski Institutional Review Board IRB "did not adhere to the applicable statutory requirements and FDA regulations governing the protection of human subjects. The Institute was given fifteen days to identify the steps it would take to prevent future violations.
Another warning issued in October notes that the Burzynski Clinic is advertising investigational drugs as being "safe and effective", noting:. This provision is not intended to restrict the full exchange of scientific information concerning the drug, including dissemination of scientific findings in scientific or lay media. Rather, its intent is to restrict promotional claims of safety or effectiveness of the drug for a use for which it is under investigation and to preclude commercialization of the drug before it is approved for commercial distribution.
Promoting Antineoplastons as safe and effective for the purposes for which they are under investigation, by making representations such as those noted above, is in violation of 21 CFR The letter requires cessation of noncompliant promotional activities, including use of testimonials and promotional interviews with Burzynski himself.
In June , antineoplaston trials were paused following the death of a child patient. In December , the FDA issued its findings in warning letters to Burzynski, expressing "concerns about subject safety and data integrity, as well as concerns about the adequacy of safeguards in place at your site to protect patients In November the FDA released the observational notes from an inspection of Burzynski as a principal investigator that took place between January and March Further, the FDA told Burzynski, "You failed to protect the rights, safety, and welfare of subjects under your care.
Forty-eight 48 subjects experienced investigational overdoses between January 1, and February 22, [ Lastly, the FDA observed: "Your [ In Burzynski's written response to the FDA investigation he states that the investigators '"complied with all criteria for evaluation of response and made accurate assessments for tumor response. The letter to Burzynski noted serious problems with patient medical files with respect to a pediatric patient who died while treated by Burzynski  and whose death apparently initiated the investigation.
On March 23, , USA Today reported that the FDA had decided to permit "a handful" of cancer patients to receive Burzynski's treatment provided that the patients did not receive the treatment directly from him. David Gorski wrote in that over four decades the FDA and state medical boards have been unable to shut down Burzynkski's business selling unproven treatments — "these organizations are supposed to protect the public from practitioners like Burzynski, but all too often they fail at their charges, in this case spectacularly.
The Burzynski Clinic has also made use of compassionate use exemptions. According to an investigative report by STAT News published in August , the clinic has benefited by political lobbying of Burzynski's supporters, including the families of patients with terminal diagnoses.
However, appeals to the FDA compassionate use exemptions are not always successful. In one case, "Burzynski said he used a Texas state law to circumvent the agency and start treatment. In December , the use of chemotherapeutic agents by the clinic has been characterized as "random" and their use of unapproved combinations "with no known benefits but clear harms" by the Texas Medical Board , which regulates and licenses physicians in the state of Texas, led to a case against Burzynski by that board.
Burzynski was acquitted because he had not personally written the prescriptions. Burzynski was accused of bait-and-switch tactics, improperly charging patients, not informing patients that he owns the pharmacy they were required to use to fill their medications, and of off-label prescribing of drugs. Burzynski through his current attorney denied all charges.
In , a federal court issued an injunction against Burzynski, barring him from shipping antineoplastons in interstate commerce without FDA approval. Burzynski continued to use antineoplastons and was charged with 75 federal counts of mail fraud and violations of federal drug laws. In , a day trial resulted in the dismissal of the 34 counts of mail fraud.
On the other 41 counts, the jury deadlocked, failing to come to a verdict. An administrative law judge ruled that Burzynski violated a section of the Texas Health and Safety Code dealing with prescriptions for unapproved drugs.
The Texas Court of Appeals ultimately upheld this determination in a decision. She sued for negligence, negligent misrepresentation, fraud, deceptive trade and conspiracy.
Following the publicity fallout resulting from the legal threats made by Stephens against the bloggers, the Burzynski Clinic issued a press release on November 29, confirming that the Clinic had hired Stephens "to provide web optimization services and to attempt to stop the dissemination of false and inaccurate information concerning Dr.
Burzynski and the Clinic",  apologizing for comments made by Stephens to bloggers and for the posting of personal information, and announcing that Stephens "no longer has a professional relationship with the Burzynski Clinic. The chief clinician at Cancer Research UK expressed his concern at the treatment offered, and Andy Lewis of Quackometer and science writer Simon Singh , who had previously been sued by the British Chiropractic Association , said that English libel law harms public discussion of science and medicine, and thus public health.
In an article in Skeptical Inquirer published in March , skeptic Robert Blaskiewicz chronicled the activities by skeptics to investigate and challenge Burzynski's claim of cancer treatments. He claimed aggressive actions by Burzynski's supporters toward the critics, including contacting their employers, lodging complaints to state licensing boards and defamation.
Blaskiewicz pointedly indicated that, although Burzynski had dismissed Marc Stephens, his clinic has not retracted the warnings of the possibility of lawsuits against critics, that it is "a threat that hangs over all of these activists every day". From Wikipedia, the free encyclopedia. For definitions of clinical trial phases, see clinical trial. The Canadian Journal of Sociology. Retrieved May 10, Stanislaw R. Burzynski, Tomasz J. Janicki, Gregory S.
Burzynski, Ania Marszalek". Childs Nerv Syst. Houston Press. Integrative Cancer Therapies. Page accessed March 14, Drugs Under Experimental and Clinical Research. Bibcode : Sci Stanislaw Burzynski's "personalized gene-targeted cancer therapy": Can he do what he claims for cancer?
December 12, Dr. March USA Today. Retrieved November 15, American Cancer Society. November Archived from the original on July 21, Retrieved September 5,
Doctor accused of selling false hope to families
The 6-year-old boy had been fighting an inoperable brain tumor for 10 months. When his mother, Niasia Cotto, found him in his bed, unresponsive and unable to open his eyes, "we knew there was nothing else that we could do," she said. An ambulance took Josia to a hospice room at a local hospital. His parents covered him in a soft, blue-and-white blanket, hugged him and held his small hand for the last time. Clinging to hope, the Linden, N.
Would you like to tell us about a lower price? If you are a seller for this product, would you like to suggest updates through seller support? This is the definitive book about Dr. Stanislaw Burzynski's antineoplaston treatment for cancer, which has put thousands of cancers into remission and is at last on the road to full drug approval from the FDA.